Stockscreener 앱 받기
8.41
0.36%
-0.03
시간 외 거래:
8.20
-0.21
-2.50%
전일 마감가:
$8.44
열려 있는:
$8.25
하루 거래량:
275.40K
Relative Volume:
1.25
시가총액:
$416.05M
수익:
$62.02M
순이익/손실:
$-45.65M
주가수익비율:
-9.1413
EPS:
-0.92
순현금흐름:
$-9.60M
1주 성능:
-5.82%
1개월 성능:
-11.75%
6개월 성능:
+4.47%
1년 성능:
-9.67%
1일 변동 폭
$7.90
$8.66
1주일 범위
$7.90
$9.1975
52주 변동 폭
$7.44
$10.90
Theravance Biopharma Inc Stock (TBPH) Company Profile
명칭
Theravance Biopharma Inc
전화
650-808-6000
주소
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
TBPH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
8.41 | 416.05M | 62.02M | -45.65M | -9.60M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-06 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-04-12 | 개시 | BTIG Research | Buy |
| 2024-01-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-11-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-09-15 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-08-25 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2020-10-14 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | 개시 | JP Morgan | Overweight |
| 2020-06-15 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-05-13 | 개시 | Cowen | Outperform |
| 2020-01-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-06 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | 개시 | H.C. Wainwright | Buy |
| 2018-03-29 | 재개 | Piper Jaffray | Overweight |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-05-11 | 재확인 | Needham | Buy |
| 2016-12-21 | 개시 | Needham | Buy |
| 2016-11-03 | 개시 | Piper Jaffray | Overweight |
| 2016-10-12 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | 개시 | Guggenheim | Buy |
| 2016-06-20 | 재확인 | Leerink Partners | Outperform |
| 2016-05-12 | 개시 | Leerink Partners | Outperform |
| 2016-05-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
모두보기
Theravance Biopharma Inc 주식(TBPH)의 최신 뉴스
Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting - PR Newswire
Teacher Retirement System of Texas Takes $103,000 Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance biopharma SVP Rhonda Farnum sells $36,000 in shares - MSN
Exclusive Access: Theravance Biopharma Leadership Reveals Strategy at Jones Healthcare Conference - Stock Titan
Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report? - Yahoo Finance
Charles Schwab Investment Management Inc. Has $2.77 Million Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology - PR Newswire
Bank of New York Mellon Corp Sells 5,282 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $13.75 Consensus Price Target from Brokerages - Defense World
Q1 EPS Forecast for Theravance Biopharma Reduced by Analyst - Defense World
(TBPH) Investment Analysis - news.stocktradersdaily.com
Theravance Biopharma (NASDAQ:TBPH) Stock Crosses Above 50-Day Moving Average – What’s Next? - Defense World
Theravance Biopharma: Clinical Progress Is Not Enough To Make It Attractive - Seeking Alpha
Rhumbline Advisers Sells 3,110 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance Biopharma Inc to Host Earnings Call - ACCESS Newswire
Theravance Biopharma, Inc. to Host Earnings Call - ACCESS Newswire
Zacks Research Brokers Lower Earnings Estimates for TBPH - Armenian Reporter
What is Zacks Research’s Forecast for TBPH Q1 Earnings? - Defense World
Where are the Opportunities in (TBPH) - news.stocktradersdaily.com
Equities Analysts Issue Forecasts for TBPH FY2028 Earnings - MarketBeat
Theravance Biopharma (NASDAQ:TBPH) Share Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat
Analysts Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75 - MarketBeat
HC Wainwright Reiterates Buy Rating for Theravance Biopharma (NASDAQ:TBPH) - MarketBeat
Theravance Biopharma Reports Strong Q4 2024 Earnings - TipRanks
Investor Network: Theravance Biopharma Inc to Host Earnings Call - ACCESS Newswire
Research Analysts Issue Forecasts for TBPH FY2024 Earnings - Defense World
Theravance Biopharma (NASDAQ:TBPH) Releases Earnings Results, Misses Estimates By $0.26 EPS - MarketBeat
Theravance's Q4 Loss In Line With Estimates, Sales Beat - Yahoo
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2024 Earnings Call Transcript - Insider Monkey
FY2024 Earnings Forecast for TBPH Issued By HC Wainwright - MarketBeat
HC Wainwright Reiterates “Buy” Rating for Theravance Biopharma (NASDAQ:TBPH) - Defense World
Theravance Biopharma Inc (TBPH) Q4 2024 Earnings Call Highlights: Record Sales and Strategic ... By GuruFocus - Investing.com Canada
Theravance Biopharma Inc (TBPH) Q4 2024 Earnings Call Highlights: Record Sales and Strategic ... - Yahoo Finance
What is HC Wainwright’s Estimate for TBPH FY2028 Earnings? - Defense World
Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates - MSN
Theravance Biopharma Reports Record 2024 Financial Results - TipRanks
Theravance Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results - PR Newswire
Earnings To Watch: Theravance Biopharma Inc (TBPH) Reports Q4 20 - GuruFocus
Earnings To Watch: Theravance Biopharma Inc (TBPH) Reports Q4 2024 Result - Yahoo Finance
Theravance Biopharma: Strategic Milestones and Revenue Forecasts Justify Buy Rating - TipRanks
Theravance Biopharma Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
Theravance Biopharma (TBPH) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Inside Access: Theravance Biopharma's Strategic Update at Elite Healthcare Conference - StockTitan
(TBPH) Technical Data - Stock Traders Daily
Here's Why We're Not At All Concerned With Theravance Biopharma's (NASDAQ:TBPH) Cash Burn Situation - Yahoo Finance
Theravance Biopharma Earnings: Key Financial Results Coming February 26What's Next for TBPH? - StockTitan
TBPHTheravance Biopharma, Inc. Latest Stock News & Market Updates - StockTitan
Theravance Biopharma to Participate in an Upcoming Investor Conference - PR Newswire
Theravance Biopharma Inc (TBPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.48%
자본화:
|
볼륨(24시간):